Les carcinomes bronchopulmonaires à petites cellules en 2011: quoi de neuf ?

Small cells lung cancer (SCLC) represents less than 15% of all the lung cancers. Prognostic depend of the extend of the disease. When it is easily accessible and does not delay management of disease the realization of a FDG scintigraphy allows to assert the localized character of the disease and to justify a aggressive attitude. The recent progress concerns essentially the modalities of the radiotherapy (concomitant administration with chemotherapy, count of doses and division of doses). The cranial prophylactic irradiation is a standard for patients who respond to chemotherapy. The chemotherapies of second and of the third line are recommended. There is no new promising molecule outside maybe amburicine. The targeted therapies showed disappointing results. Today, very few clinical trials concern NSCL, which becomes a “orphan” disease.